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Purpose: To examine the association between diabetes and risk of medical glaucoma treatment 
and to assess the role of long-term glycemic control in the putative association.
Design: Population-based case-control study.
Methods: Cases of treated glaucoma were all persons filling at least three prescriptions for 
glaucoma medication for the first time within one year between 2001 and 2006 in Northern 
Jutland, Denmark. We used risk set sampling to select 10 gender- and age-matched general 
population controls per case using the Danish Civil Registration System. Data on diabetes, 
comorbidities, and laboratory tests, including glycosylated hemoglobin (as a measure of glycemic 
control) were obtained from population-based medical registries. We calculated odds ratio 
(OR) as an estimate of relative risk for treated glaucoma comparing patients with and without 
diabetes, adjusted for comorbid conditions and medication use.
Results: We included 5,991 persons with incident medical glaucoma treatment and 59,910 
population controls. The adjusted OR for treated glaucoma for patients with diabetes was 1.81 
(95% confidence interval: 1.65–1.98). The strength of the association between diabetes and 
glaucoma risk did not vary by diabetes duration or by the level of glycemic control.
Conclusions: Regardless of glycemic control, diabetes is associated with a substantially 
increased risk for medical glaucoma treatment.
Keywords: diabetes, glaucoma, glycemic control, prescriptions, population-based case-control 
study
Introduction
The morbidity, mortality and costs related to diabetes are escalating epidemically. 
A US citizen born in 2000 will have a 33% lifetime risk of developing diabetes.1–3 Eye 
complications are important adverse effects of diabetes. Reduced intraocular blood 
flow in diabetic patients causes secondary nerve cell damage and leads to diabetic 
retinopathy.4 Diabetes may also cause a thicker central corneal thickness5 and a rise 
in intraocular pressure (IOP)6,7 made worse by poor long-term control of diabetes.6 
Long-term control of diabetes can be assessed with measurements of glycosylated 
hemoglobin (HbA1c).8,9
Glaucoma is the most common cause of irreversible blindness worldwide.10 The 
visual field loss in glaucoma caused by loss of retinal nerve cells can be worsened 
by nerve cell apoptosis, which is increased in diabetic patients. The previous epide-
miologic studies that examined diabetes as a potential risk factor for glaucoma had 
conflicting conclusions.7,11–16 Moreover, while hyperglycemia is known to play a role 
in the development of diabetic retinopathy, to our knowledge no study has examined Clinical Epidemiology 2009:1 126
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the association between the level of glycemic control and 
risk of glaucoma.
We hypothesized that diabetes is a risk factor for 
glaucoma, and that poor long-term glycemic control and 
longer duration of diabetes may increase the risk of glaucoma. 
We conducted a large case-control study using population-
based Danish medical databases.
Methods
We conducted the study in the former Danish counties of 
Northern Jutland and Aarhus, with a total population of 
1.14 million mixed rural and urban inhabitants, representing 
20% of the Danish population.17 The population is 93% 
Caucasian, and less than 2% migrate annually from or into 
the counties.17 The Danish National Health Service provides 
tax-financed primary medical care and free access to hospi-
tals to all citizens. Furthermore, the National Health Service 
partially reimburses the costs of prescription medications, 
including those for glaucoma and diabetes. We linked data 
from several Danish population-based databases and medical 
registries. The unambiguous individual-level linkage is pos-
sible thanks to the Danish Civil Registration System, whereby 
a unique 10-digit civil registration number (CRN) encoding 
date of birth and sex is assigned to every Danish citizen at 
birth. The Civil Registration System18 was established in 
1968. It is updated daily and tracks vital status, residence, 
and migrations. The CRN is used in all public databases to 
uniquely identify individuals.18
Cases of medically treated glaucoma
Glaucoma treatment cases were identified and categorized 
using the Danish National Registry of Patients (DNRP)19 and 
prescription databases of the two former counties merged 
into a research database at Aarhus University. Established in 
1977, the DNRP tracks all hospitalizations and, from 1994 
onwards, all outpatient visits. Recorded data include dates of 
admission and discharge, surgical procedures performed, and 
up to 20 diagnoses per visit or hospitalization. The diagnoses 
are coded by medical doctors using the 8th revision of the 
International Classification of Diseases (ICD-8) through 
the end of 1993 and the 10th revision (ICD-10) thereafter. 
The prescription databases hold information on every sale 
of prescription medication in the counties, including date of 
dispensing and type of drug coded according to the Anatomical 
Therapeutic Chemical (ATC) classification system.
We defined an incident case of glaucoma treatment as 
a person filling three or more prescriptions for a glaucoma 
medication (ATC code group S01E) over 365 days or less 
during the study period, from January 1st, 2001 to December 
31st, 2006. We required a minimum of three filled prescriptions 
on separate dates in order to exclude cases of possible short-
term secondary glaucoma associated with prior ocular surgery 
or uveitis. Glaucoma medication is sold only by prescription 
in Denmark and is prescribed for primary or secondary glau-
coma or for ocular hypertension (OHT), but not for any other 
condition. We did not consider as cases patients with prescrip-
tion for Acetazolamide tablets (ATC code S01 EC01), since 
these are used for other indications, including high-altitude 
sickness; moreover, they are rarely used for long-term glau-
coma treatment. The date on which the patient filled his or her 
third prescription for a glaucoma medication was considered 
the glaucoma case index date. In order to be eligible for inclu-
sion in the study, persons had to reside in one of the counties 
for at least five years before the index date. In order to only 
include patients with incident glaucoma, we excluded persons 
with prescriptions for a glaucoma medication filled within five 
years prior to the beginning of the study period and patients with 
a previous hospital contact with angle-closure glaucoma in the 
DNRP (ICD-10 diagnosis H40.2). We also excluded patients 
with glaucoma surgery or laser treatment prior to index date 
(procedure codes KCHD all, or KCHF 05-10-15-20-30 or 99, 
obtained from the DNRP). We identified incident glaucoma 
cases based on glaucoma medications rather than ICD-10 
codes in our study because the majority of glaucoma patients 
in Denmark are treated in private practices that do not report 
diagnosis codes to the DNRP.
Population controls
Using data from the Civil Registration System to ascertain 
vital status and residence at the time of sampling, we ran-
domly selected 10 population controls for each glaucoma 
case, matching birth-year, sex, and residence in one of the 
two counties for at least five years prior to the case’s index 
date. Control selection was done by risk set sampling,20,21 
whereby controls had to be alive and at risk of filling their 
third prescription for a glaucoma medication on the index 
date of their corresponding case. Odds ratios (OR) calcu-
lated from samples drawn using risk-set sampling provide 
estimates of the incidence rate ratio that would be observed 
in the underlying cohort.22 In this study OR was used as a 
measure of relative risk. The same eligibility and exclusion 
criteria were applied to cases and controls.
Identification of diabetes
Presence of diabetes for all subjects was ascertained by a 
validated method using prescription and hospital data.23 Clinical Epidemiology 2009:1 127
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We used the DNRP to identify all persons with a hospitalization 
or outpatient diagnosis of diabetes mellitus recorded since 
1977 (ICD-8 codes 249–250 and ICD-10 codes E10–14). 
From the counties’ prescription databases we identified all 
persons with at least one prescription for insulin or an oral 
antidiabetic drug.
Diabetes was classified as type 1 diabetes mellitus (T1DM) 
for patients first diagnosed before the age of 30 years, treated 
with insulin monotherapy, and without history of taking an 
oral antidiabetic medication; the remaining diabetes patients 
were considered to have type 2 diabetes mellitus (T2DM). 
The use of insulin and oral antidiabetic medication was ascer-
tained by selecting prescriptions with ATC codes A10A and 
A10B recorded in the prescription databases.23,24 Duration 
of diabetes was computed as the time elapsed from the first 
record of diabetes treatment or hospital diagnosis until the 
index date. Information on HbA1c levels was obtained by 
linkage of the regional laboratory databases.25 These data-
bases contain information on all specimens submitted for 
analysis by hospitals and practitioners, including the exact 
time of blood sample collection. The most recent measure-
ment was used for analysis. We only could identify 27 T1DM 
patients in the case group; of these, 25 (93%) had vitreoretinal 
surgery recorded before the index date, indicating secondary 
glaucoma. We refrained from making individual analysis on 
T1DM patients as this subgroup was too small and analyzed 
all diabetes patients together.
Covariates
We retrieved data on variables that are putative risk factors 
for glaucoma and also may be associated with diabetes. 
A recent review article identified cardiovascular events, 
hypertension, thyroid disease and migraine as risk factors 
for glaucoma.26 We considered as potential confounders the 
following conditions, which were considered present if they 
were identified by a diagnosis in DNRP or by a relevant medi-
cation in the prescription database within five years prior to 
the index date for cases and matched controls: cardiovascular 
disease (ICD-10: E78; I20–26, 35.0–35.2, 60–61, 63–67, 
69, 70, 74, 82), hypertension (ICD-10: I10–15), thyroid 
disease (ICD-10: E01–07, O90.5 and ATC: H03), migraine 
(ICD-10: G43 and ATC: N02C), autoimmune disorders 
(ICD-10: M05–9, M30–35, D86, K50–51, MO2.3, M45.9, 
M02.9, M03.2, M03.6, I73), alcoholism-related diagnoses 
(ICD-10: F10, K86.0, Z72.1, R78.0, T51, K 29.2, G62.1, 
G72.1, G31.2, I42.6), cataract (ICD-10: H25–26, 28.0 and 
procedure codes KCJA,C,D,E), retinal detachment (ICD-10: 
H33.0 and procedure codes KCKC60,70, KCKD25,30) and 
uveitis (ICD-10: H20, 22, 30, 32.0 and ATC-codes S01BA). 
Furthermore, we ascertained use of potential IOP-lowering 
systemic drugs: oral beta-adrenoceptor blockers (ATC: C07), 
statins (ATC: C10AA), and angiotensin-converting enzyme 
(ACE) inhibitors (ATC: C02E, C02L, C09A, C09B, 
C08DA51).27–30
statistical analysis
We used conditional logistic regression to compute the 
crude and adjusted OR with 95% confidence intervals 
(CI) for glaucoma according to presence of diabetes. 
Diabetes exposure was categorized by duration of diabetes 
(5 years, 5–10 years, 10 years) and HbA1c levels 
(7%, 7%–8%, 8%–9%, 9%, unknown).8,31 
We conducted analysis stratified by sex and age group: 
0–50 years, 51–60 years, 61–70 years, 71–80 years, 
81–90 years, 90 years. We adjusted for cardiovascular 
disease, hypertension, thyroid disease, other autoimmune 
disorders, migraine, alcoholism-related disorders, and use 
of ACE inhibitors, beta-blockers, and statins. Analyses were 
conducted both with and without adjustment for retinal 
detachment, cataracts, and uveitis, as these conditions 
could represent intermediate steps between diabetes and 
development of glaucoma. All analyses were performed 
using Stata software (version 9.2; StataCorp, College 
Station, TX, USA).
Results
From January 1st, 2001 to December 31st, 2006, 9,295 
patients filled at least one prescription for glaucoma 
medication in the counties’ pharmacies; of these, 6,737 
filled at least three prescriptions on different dates. Of these, 
268 patients had more than 365 days between the first and the 
third glaucoma medication prescription, 384 patients moved 
away from the counties, and 94 patients had a history of 
angle-closure glaucoma or other glaucoma, laser treatment or 
surgery, and were therefore excluded, leaving 5,991 patients 
with medically treated incident glaucoma for analysis. Table 1 
has descriptive data of the 5,991 cases with treated incident 
glaucoma and the 59,910 age- and sex-matched control 
subjects. Seven hundred and four patients using glaucoma 
medication had diabetes (11.8%) compared with 3,975 
(6.6%) of the 59,910 controls. Patients using glaucoma medi-
cation were substantially more likely than controls to have 
a history of uveitis, cataract, and retinal detachment. Most 
other comorbidities and use of medications were slightly 
more prevalent among glaucoma cases than among matched 
controls (Table 1).Clinical Epidemiology 2009:1 128
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The crude OR for using glaucoma medication in patients 
with diabetes was 1.95 (95% CI: 1.79–2.12) (Table 1). 
After adjusting for confounding factors, the OR decreased 
slightly to 1.81 (95% CI: 1.65–1.98). When the eye disor-
ders of retinal detachment, cataracts, and uveitis were added 
to the model, the OR further decreased slightly, to 1.75 
(95% CI: 1.60–1.92).
One or more measurement of HbA1c within the year 
prior to index date was available for 535 patients treated 
with glaucoma medication (73.3%) with diabetes and for 
2,535 of the controls (63.0%) with diabetes. Diabetes was 
associated with about twofold increased risk for glaucoma 
at all levels of HbA1c: adjusted ORs among diabetic subjects 
with an HbA1c level of 7%, 7%–8%, 8%–9%, 
and 9% were 1.97 (95% CI: 1.69–2.30), 2.24 (95% CI: 
1.86–2.69), 2.05 (95% CI: 1.62–2.60), and 2.20 (95% CI: 
1.73–2.80), respectively (Table 1). Fifty-six percent of the 
diabetes patients who used glaucoma medication had had 
diabetes for more than five years. The duration of diabetes did 
not modify relative risk estimates considerably: OR = 1.88 
(95% CI: 1.66–2.14) for diabetes duration under five years, 
OR = 1.64 (95% CI: 1.41–1.92) for duration between five 
Table 1 Adjusted and crude ORs for glaucoma according to presence of diabetes mellitus
Risk factor Cases Controls Crude OR (95% CI) Adjusted ORa (95% CI)
Sex
Male 2,492 (41.6) 24,920 (41.6)
Female 3,499 (58.4) 34,990 (58.4)
Age, years, median (iQR) 70.4 (60.8–78.4) 70.3 (60.8–78.4)
Diabetes
Absent 5,287 (88.25) 55,935 (93.37) 1.0 (ref) 1.0 (ref)
Present 704 (11.75) 3,975 (6.63) 1.95 (1.79–2.12) 1.81 (1.65–1.98)
Thyroid disease 439 (7.3) 3,603 (6.0) 1.24 (1.12–1.38) 1.20 (1.08–1.34)
Migraine 203 (3.4) 1,568 (2.6) 1.31 (1.13–1.53) 1.32 (1.13–1.54)
Auto immune disorders 244 (4.1) 1,915 (3.2) 1.29 (1.12–1.47) 1.25 (1.09–1.43)
Cardiovascular risk factors 765 (12.8) 7,919 (13.2) 0.96 (0.88–1.04) 0.76 (0.70–0.84)
hypertension 593 (9.9) 4,772 (8.0) 1.28 (1.17–1.40) 1.19 (1.07–1.31)
Alcohol related diagnoses 47 (0.8) 494 (0.8) 0.95 (0.70–1.29) 0.91 (0.68–1.24)
ACE inhibitors 1,042 (17.4) 8,616 (14.4) 1.26 (1.18–1.36) 1.08 (1.00–1.17)
Oral beta adrenoceptor 
blockers
1217 (20.3) 11,695 (19.5) 1.05 (0.98–1.13) 0.96 (0.89–1.03)
statins 828 (13.8) 6,307 (10.5) 1.05 (0.98–1.13) 1.29 (1.18–1.41)
Cataract 686 (11.5) 3,995 (6.7) 1.90 (1.74–2.08) 1.42 (1.29–1.56)
Retinal detachment 135 (2.3) 159 (0.3) 8.65 (6.86–10.90) 6.15 (4.82–7.85)
Uveitis 523 (8.7) 1,349 (2.3) 4.21 (3.79–4.68) 3.60 (3.22–4.02)
Duration of diabetes
Diabetes absent 5,287 (88.25) 55,935 (93.37) 1.0 (ref) 1.0 (ref)
5 years 320 (5.34) 1,689 (2.82) 1.88 (1.66–2.14) 2.03 (1.79–2.29)
5–10 years 200 (3.34) 1,210 (2.02) 1.64 (1.41–1.92) 1.77 (1.52–2.06)
10 years 211 (3.52) 1,111 (1.85) 1.87 (1.60–2.18) 2.02 (1.74–2.35)
HbA1c
Diabetes absent 5,287 (87.3) 55,935 (93.37) 1.0 (ref) 1.0 (ref)
hbA1c  7% 213 (3.6) 1,074 (1.79) 1.97 (1.69–2.30) 2.12 (1.83–2.47)
hbA1c  7%–8% 150 (2.5) 660 (1.10) 2.24 (1.86–2.69) 2.44 (2.04–2.92)
hbA1c  8%–9% 88 (1.5) 421 (0.70) 2.05 (1.62–2.60) 2.24 (1.77–2.82)
hbA1c  9% 84 (1.4) 380 (0.63) 2.20 (1.73–2.80) 2.36 (1.86–3.00)
hbA1c unknown 196 (3.3) 1,475 (2.46) 1.34 (1.15–1.57) 1.41 (1.21–1.65)
Notes: Data on cases and controls are n (%). aOR adjusted by conditional logistic regression for thyroid disease, migraine, autoimmune disorders, cardiovascular events, 
hypertension, alcohol-related disorders, angiotensin-converting enzyme inhibitors, oral beta adrenoceptor blockers and statins.
Abbreviations: ACE, angiotensin-converting enzyme; CI, confidence interval; HbA1c, glycosylated hemoglobin; iQ, interquartile range; OR, odds ratio.Clinical Epidemiology 2009:1 129
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and 10 years, and OR = 1.87 (95% CI: 1.60–2.18, n = 200) 
for duration of more than 10 years.
The strength of association between diabetes and risk of 
using glaucoma medication decreased with age, with OR 
decreasing from 3.35 (95% CI: 3.50–5.08) for patients aged 
60 years or younger to 1.12 (95% CI: 0.91–1.31) for patients 
older than 80 years. The effect of diabetes was greater among 
men with OR = 2.04 (95% CI: 1.79–2.31) than among women 
with OR = 1.61 (95% CI: 1.42–1.83) (Table 2).
Discussion
We found that diabetes mellitus was associated with a 1.8-fold 
increased risk of medically treated glaucoma. The increased 
risk was independent of diabetes duration or of level of 
glycemic control. The relative effect associated with diabetes 
was greatest among persons aged under 60 years, possibly due 
to the lower baseline glaucoma risk in younger individuals. 
The effect was greater in men than in women.
The effect of diabetes on the risk of using glaucoma 
medication estimated in our study was similar to that esti-
mated in the only other study of comparable size and design. 
In the Scottish Tayside study (2000), a cohort of all T2DM 
patients (n = 6,631) in the Tayside region was followed 
for two years between 1993 and 1995.32 The investigators 
used prescription data and operation codes as surrogate 
measures for glaucoma, while estimating, based on a case 
notes review, the extent of misclassification thus introduced. 
Based on 65 incident glaucoma cases in the T2DM cohort 
and 963 incident cases in the general Tayside population, 
relative risk was estimated at 1.57 (95% CI: 0.99–2.48) for 
the association between T2DM and glaucoma. Four large 
cross-sectional studies found positive associations between 
diabetes and glaucoma including the Beaver Dam study 
(1994; OR = 1.84; n = 4,926, glaucoma cases = 105);11 the 
Rotterdam study (1995; OR = 3.11; n = 4,178, glaucoma 
cases = 37);7 the Blue Mountain Eye study (1997; OR = 2.12; 
n = 3,654, glaucoma cases = 108);12 and the Los Angeles 
Latino Eye Study (LALES, 2008; OR = 1.4; n = 5,894, 
glaucoma cases = 288).13 Other cross-sectional studies, 
including the Baltimore Eye Survey (n = 5,308, glaucoma 
cases = 161)15 and the Ocular Hypertension Treatment 
Study (n = 1,636, glaucoma cases = 119)14 showed no or 
even a negative association between diabetes and glaucoma. 
A meta-analysis that included most of the case-control and 
cross-sectional studies concluded that diabetes patients are 
at a significantly increased risk of glaucoma (OR = 1.5, 
95% CI: 1.16–1.93).33 Two recent prospective population-
based cohort studies found no association between diabetes 
and incident glaucoma: the Barbados Eye Study cohort 
(n = 3,222, glaucoma cases = 125, OR diabetes = 1.2) was 
followed for nine years16 and the Rotterdam cohort (n = 3,387, 
glaucoma cases = 87, OR diabetes = 0.82,) was followed for 
seven years.34 In two subsequent letters, Ellis and Quigley 
propose that a potential surveillance bias in diabetic patients 
in previous studies may fully explain the apparent increased 
risk of glaucoma in diabetes patients.35,36 Our study is the 
first to demonstrate the equal risk of glaucoma associated 
with diabetes at all levels of glycemic control and duration 
of diabetes.
Our findings must be interpreted in the context of the 
study’s methodological strengths and weaknesses. The 
universal health coverage of Denmark’s national health 
care system enabled us to conduct a large, truly population-
based study, while using population-based data sources with 
independently and routinely recorded data. These features 
tend to reduce the risks of selection and information bias. 
As in previous studies of this issue, it is difficult to rule 
out surveillance bias stemming from greater likelihood of 
diabetic patients to undergo ophthalmological investiga-
tions compared with general population.11,32,34–36 As shown 
in the Beaver Dam study, diabetes patients with glaucoma 
were significantly more likely than glaucoma patients with-
out diabetes to have consulted an ophthalmologist over a 
two-year period (49.2 vs 39.6%).11 Some evidence for such 
bias in our data comes from the observation that glaucoma 
patients with diabetes tended to be slightly younger than other 
glaucoma patients (median age of 68.8 years vs. 71.1 years). 
Moreover, our case group is likely to include patients treated 
for OHT as in the Tayside Study.32 Our data did not allow us 
to differentiate primary from secondary glaucoma, neither 
Table 2 Odds ratio (OR) for glaucoma according to presence 
of diabetes stratified by age and sex
Crude OR (95% CI) Adjusted ORa (95% CI)
Age
0–60 years 4.22 (3.50–5.08) 3.35 (2.72–4.14)
61–70 years 2.55 (2.17–2.99) 2.26 (1.90–2.69)
71–80 years 1.54 (1.32–1.79) 1.47 (1.25–1.73)
80 years 1.08 (0.89–1.33) 1.12 (0.91–1.37)
Sex
  Female 1.74 (1.54–1.96) 1.61 (1.42–1.83)
  Male 2.20 (1.95–2.49) 2.04 (1.79–2.31)
Notes: aOdds ratio adjusted by conditional logistic regression for thyroid disease, 
migraine, autoimmune disorders, cardiovascular events, hypertension, alcohol related 
disorders, ace-inhibitors, oral beta adrenoceptor blockers and statins.
Abbreviation: CI, confidence interval.Clinical Epidemiology 2009:1 130
Welinder et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
could we differentiate between different types of glaucoma 
(pseudoexfoliation, angle closure, pigment dispersion, etc). 
Also, glaucoma diagnoses in this population-based study 
were made by approximately 60 different ophthalmologists 
who may have had different thresholds for commencement 
of medical treatment for glaucoma. Quigley and colleagues 
suggested that it is not safe to conclude that most physicians 
prescribe glaucoma medication according to preferred prac-
tice patterns, and that many patients fill their prescriptions so 
irregularly that they keep “reappearing” as incident glaucoma 
cases.37 We aimed to solve this potential problem with our 
defined medication algorithm.
Ascertainment of medication use and of data on 
covariates through independent administrative registries 
reduced potential patient-related (differential recall) or 
investigator-related information bias, which might affect 
studies with primary data collection. In order to become a 
glaucoma case in this study, patients had to buy glaucoma 
medication at least three different times within one year. 
These cases are very likely to actually use the medication 
and to have glaucoma rather than a temporary increase in 
IOP. Prescriptions can only be filled at a pharmacy, and all 
Danish pharmacies report complete data to the prescription 
database. Glaucoma medications purchased in pharmacies 
are partially refunded by the national health insurance, 
and the share of Internet-based or foreign purchases is 
negligibly small.
We were able to adjust our analysis for several potential 
confounders measured by data from the medical databases 
that aim to track complete prescription and medical history, 
including all surgical procedures performed. Known strong 
risk factors for glaucoma are older age, family history, and 
race. Hispanics13 and blacks16,38 are known to have a higher 
risk than Caucasians for both diabetes and glaucoma, but are 
hardly represented in this study performed in a very homoge-
nous population of Caucasians. Most of the recently reviewed 
risk factors for glaucoma26 were more prevalent among cases 
than among controls in our study, but adjustment for their 
effects explained only 15%–20% of the observed diabetes 
effect. Of note, cardiovascular disease did not confound our 
analysis. While cardiovascular diseases and hypertension 
were associated with diabetes, they were equally prevalent 
among glaucoma cases and controls, which suggests that 
only a small part of the risk increase conferred by diabetes 
was mediated by these disorders.
In conclusion, our findings, representing the everyday 
practice pattern of Danish ophthalmologists, and based on a 
large population-based sample, corroborate and extend the 
existing evidence of diabetes mellitus as a risk factor for 
medical glaucoma treatment.
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